Search

Your search keyword '"Zoncada, A"' showing total 145 results

Search Constraints

Start Over You searched for: Author "Zoncada, A" Remove constraint Author: "Zoncada, A"
145 results on '"Zoncada, A"'

Search Results

1. Use of ICD-9-CM coding for identifying antibiotic prescriptions during hospitalization: a Delphi consensus model

2. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

3. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

4. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

5. Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study

6. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

7. Use of ICD-9-CM coding for identifying antibiotic prescriptions during hospitalization: a Delphi consensus model

8. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure

9. Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case–Control Study

10. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

11. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

12. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

13. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

14. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure

15. Community-acquired Methicillin-Resistant Staphylococcus aureus ST398 Infection, Italy

17. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure

18. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

19. Suggestions from Cremona, Italy: 2 months into the pandemic at the frontline of COVID-19 in Europe

20. A case of mumps encephalitis imported to Italy from India

21. Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA

22. HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America.

23. Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA

28. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

29. A case of mumps encephalitis imported to Italy from India

30. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

31. Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

33. Community-acquired methicillin-resistant Staphylococcus aureus ST398 infection, Italy

34. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study

35. THU-131-Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks

36. Pretreatment HIV drug Resistance and Treatment Failure in Non-Italian HIV-1-Infected Patients Enrolled in ARCA

37. Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks

38. THU-131-Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks

39. Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks

40. Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort)

41. Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy

42. Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

43. Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

44. Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort)

45. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study

46. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study

47. Meticillin-resistant Staphylococcus aureus control in an intensive care unit: a 10 year analysis

48. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort

49. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis

50. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study

Catalog

Books, media, physical & digital resources